In vivo reversion to normal of inherited mutations in humans.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesIn vivo correction of ZAP-70 immunodeficiency by intrathymic gene transferNew approaches to treatment of primary immunodeficiencies: fixing mutations with chemicalsGene therapy for severe combined immunodeficiency: are we there yet?Role of Biomarkers in the Development of PARP InhibitorsSomatic mosaicism in the human genomeThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisThe inherited bone marrow failure syndromesPhysiological consequences of defects in ERCC1-XPF DNA repair endonucleaseRepublished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetimeThe Rules of Variation Expanded, Implications for the Research on Compatible GenomicsNon-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetimeRevertant mosaicism in skin: natural gene therapyPARP inhibitor treatment in ovarian and breast cancerMultiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.Inherited bone marrow failure syndromes in adolescents and young adults.PARP inhibitors: its role in treatment of cancer.Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita.Genetic, environmental and stochastic factors in monozygotic twin discordance with a focus on epigenetic differences.Clinical applications of Genome Polymorphism Scans.Secondary mutations of BRCA1/2 and drug resistanceChromothriptic cure of WHIM syndrome.Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype."...Rewritten in the skin": clues to skin biology and aging from inherited disease.Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus.Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreductionReversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1)Mitotic Intragenic Recombination: A Mechanism of Survival for Several Congenital Disorders of GlycosylationUnprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome.Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersInsertional mutagenesis and clonal dominance: biological and statistical considerations.Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.Single lobe disease in cases of advanced endemic goiter: a new phenotype.Fanconi anemia: a signal transduction and DNA repair pathway.Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosaDetecting somatic mosaicism: considerations and clinical implications.The origins, determinants, and consequences of human mutations.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
P2860
Q21129302-FA163EF2-1D33-46CB-BEF6-C867642C9798Q24532255-81C394C9-2B0D-40FF-98FA-ADF3D0F6A884Q24656619-30C50F0E-B109-4039-AD08-2E33E5199360Q24680426-072338E1-CD2E-4579-8B5C-337D214E9046Q26753159-2CC78E4E-4A41-45EF-A9AB-F92B29D97DF4Q26823199-A8796304-4DDC-42B2-9E1E-76859FAD6E9AQ26865888-146391E8-1CA5-4E75-AA1B-DD74EC26DF5AQ26999046-FC37820B-1536-487C-94A6-CD02CA718279Q28238547-8E6E8BD3-CA66-45A8-8A74-10938E57A79CQ28385687-20BE0BF8-72F5-4015-9099-B17C37BB54F4Q28390117-743E1C8B-163D-4F32-875E-46A6DC9133E5Q28392579-0ACECEF5-3920-4660-BD35-B577B24D28AAQ28741264-1EBA7C30-640C-4104-9C63-6E6FA298B1D8Q28741688-BE427F60-0999-4EE7-A207-052FA22BCA19Q33226033-5621A315-2FCD-4A65-A0BD-D39EB1924D2BQ33415672-7A43C9DA-FEF3-47FF-971A-C658044B6C65Q33579740-798F292C-7662-489C-934B-234D2083F814Q34124290-AA91C69A-EBEA-46F2-AE5D-588EE554F756Q34134419-7FF1FC6B-3F7B-4BC3-B959-6CEAB9213B0BQ34255048-B73D49F1-5D28-4D65-A211-9655D323D68BQ34381971-98BAA38A-D0B6-4C39-B010-5050484C04A8Q34880381-F326D600-5F0A-40A0-88D7-20AA79BA653EQ34983549-FF3657C0-5693-435F-9CD5-8F9CFD208A61Q35085186-1B9C7BD7-2988-4621-A073-0CC1D54FD6EEQ35284944-5DE02FD0-2782-4D30-920F-DE1B15ABE2B9Q35920445-9E9CA975-93C8-48AD-BE89-19F0C061F09DQ35946132-99EDAE08-CFFD-41CA-95AD-AEF8E68AB074Q36370822-4E5AFAF4-1449-442A-BDC2-FCE1E7E35EB2Q36384593-1BB18E55-CFE2-4785-BBCF-A39F1C646372Q36559149-0803CBD6-B9CE-4678-BBF8-36E2C10ED008Q36658022-62026F9C-C999-4099-B9AD-6BBC811E6137Q36958682-6BFA7342-F292-44E5-A48A-45246D447713Q36986958-CECDA15A-E8C8-4EA7-96A7-0C0D0DDF1B9CQ37194056-C3266D3B-951F-4C8C-931D-9136450CAD54Q37290894-70E7BEBB-F5C2-4AD0-9FB1-425292C71F42Q37358559-EE15C029-A36B-41C3-92EF-205FFF5F33D7Q37707008-83784864-6EC6-4980-96B1-2C3A0496708DQ38249605-BD1B63E8-01F8-4980-8ED2-90ED31591968Q38592660-19AD8AB8-CF82-4B33-9B03-370C69EE9C19Q38756892-E85464DF-3319-484F-9BED-6A24B5BF601A
P2860
In vivo reversion to normal of inherited mutations in humans.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vivo reversion to normal of inherited mutations in humans.
@ast
In vivo reversion to normal of inherited mutations in humans.
@en
type
label
In vivo reversion to normal of inherited mutations in humans.
@ast
In vivo reversion to normal of inherited mutations in humans.
@en
prefLabel
In vivo reversion to normal of inherited mutations in humans.
@ast
In vivo reversion to normal of inherited mutations in humans.
@en
P2860
P356
P1476
In vivo reversion to normal of inherited mutations in humans.
@en
P2093
Hirschhorn R
P2860
P304
P356
10.1136/JMG.40.10.721
P407
P577
2003-10-01T00:00:00Z